van der Meer, D http://orcid.org/0000-0002-0466-386X
Hoekstra, P J
van Donkelaar, M http://orcid.org/0000-0002-9112-2307
Bralten, J
Oosterlaan, J
Heslenfeld, D
Faraone, S V http://orcid.org/0000-0002-9217-3982
Franke, B http://orcid.org/0000-0003-4375-6572
Buitelaar, J K
Hartman, C A
Article History
Received: 28 November 2016
Revised: 24 April 2017
Accepted: 28 April 2017
First Online: 6 June 2017
Competing interests
: BF has received a speaker fee from Merz. PJH has received an unrestricted research grant from Shire and has been member of the advisory boards of Shire and Eli Lilly. JO has received an unrestricted investigator initiated research grant from Shire pharmaceuticals. JKB has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Eli Lilly, Shire, Novartis, Roche and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. In the past year, SVF received income, travel expenses and/or research support from Pfizer, Ironshore, Shire, Akili Interactive Labs, Alcobra, VAYA Pharma and SynapDx, and research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium–hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. SVF receives royalties from books published by Guilford Press: <i>Straight Talk about Your Child’s Mental Health</i> and Oxford University Press: <i>Schizophrenia: The Facts</i>. The remaining authors declare no conflict of interest.